FDA Approves First Drug for Postpartum Depression
https://ift.tt/2WeNHl8 WEDNESDAY, March 20, 2019 (HealthDay News) -- Postpartum depression is a common and often devastating condition for new mothers, but the U.S. Food and Drug Administration on Tuesday approved the first drug to help combat it. The drug, Zulesso (brexanolone), is delivered via intravenous infusion. "Postpartum depression is a serious condition that, when severe, can be life-threatening," noted the FDA's Dr. Tiffany Farchione. "Women may experience thoughts about harming themselves or harming their child." The condition "can also interfere with the maternal-infant bond," added Farchione, who is acting director of the Division of Psychiatry Products in the agency's Center for Drug Evaluation and Research. The FDA decision "marks the first time a drug has been specifically approved to treat postpartum depression, providing an important new treatment option," she said in an agency statement. Psychiatrist Dr. Martha Wald agreed that women battling postpartum depression have long needed new options. "There is tremendous stigma around postpartum depression for women," said Wald, a psychiatrist and psychoanalyst at Duke University, in Winston-Salem, N.C. "Many women experience great shame and feel inadequate as mothers if they struggle with depression at a time that is supposed to be joyous." "Because of this stigma, many women choose to not seek help and endure great suffering in silence," she said. "Postpartum depression affects 15 to 20 percent of the general population, and at least half of this group goes untreated. As more targeted treatments like this become available, more mothers are likely to seek and benefit from treatment." Works in a new way Dr. Kristina Deligiannidis was the lead investigator on the clinical trials that led to Zulesso's approval. She said the drug acts in a way that's different from other antidepressants. Zulesso "acts on the main inhibitory neurotransmitter system in the brain, the GABA system," explained Deligiannidis, who helps direct women's behavioral health at Zucker Hillside Hospital, in Glen Oaks, N.Y. The drug's active ingredient is synthetic allopregnanolone, a steroid that the body also makes naturally. "Allopregnanolone is known to modulate the stress response system in humans, which has been shown to be abnormally functioning in women with postpartum depression," Deligiannidis explained. Health via WebMD Health https://www.webmd.com/ March 20, 2019 at 08:56AM
The Flat Belly FixThis is the only 21-day rapid weight loss system that allows you to easily lose an average of 1 lb a day for 21 days without feeling hungry or deprived. The unique and brand new techniques used in this System are proven SAFE. And they do not cause the rebound weight gain common to all the other rapid weight loss systems that are not backed by the latest science. The Flat Belly Fix System takes advantage of a recent scientific discovery that proves the effective weight loss power of an ancient spice. Combined with other cutting-edge ingredients in the patent-pending Flat Belly Fix Tea™ — that you can make right in your own kitchen in minutes — this System is the quickest, easiest and most enjoyable way to quickly get the body you desire and deserve. Click Here
0 Comments
Leave a Reply. |
Archives
October 2020
Categories |